Writing the Next Chapter in Precision Medicines for Patients With Cancer

Discovering and developing the next generation of oncology precision medicines through:

Industry leaders with a proven track record of success

Building a broad pipeline of potentially best-in-class tumor-agnostic therapies

News

October 4, 2024
OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million
July 25, 2024
OnKure Announces the Appointment of Dylan Hartley, Ph.D. as Chief Scientific Officer
June 19, 2024
OnKure Announces the Appointment of Rogan Nunn, J.D., as General Counsel and Secretary
View All News